52 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28017532	140	Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kd inhibitors.	Astrazeneca
26652969	15	Synthesis and antitumor activity evaluation of PI3K inhibitors containing 3-substituted quinazolin-4(3H)-one moiety.	Xi'An Jiaotong University
28109945	25	Discovery of a series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as PI3K/mTOR dual inhibitors.	Hangzhou Xixi Hospital
27923617	70	Novel pyrazolo[1,5-a]pyridines with improved aqueous solubility as p110a-selective PI3 kinase inhibitors.	University of Auckland
28105286	65	Discovery of a Potent, Selective, and Orally Available PI3Kd Inhibitor for the Treatment of Inflammatory Diseases.	RhôNe-Poulenc Rorer
27660692	70	Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-¿ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate.	Infinity Pharmaceuticals
27189888	11	Optimization of the phenylurea moiety in a phosphoinositide 3-kinase (PI3K) inhibitor to improve water solubility and the PK profile by introducing a solubilizing group and ortho substituents.	Chugai Pharmaceutical
26321603	8	Synthesis and anticancer effects evaluation of 1-alkyl-3-(6-(2-methoxy-3-sulfonylaminopyridin-5-yl)benzo[d]thiazol-2-yl)urea as anticancer agents with low toxicity.	Xi'An Jiaotong University
23644197	51	Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).	University of Auckland
32551006	134	Discovery of an Atropisomeric PI3K? Selective Inhibitor through Optimization of the Hinge Binding Motif.	Gilead Sciences
30850264	108	Synthesis and biological evaluation of solubilized sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474.	University of Auckland
31851518	61	The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-	Astrazeneca
31693351	473	Discovery of 4	TBA
31228810	162	Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors.	West China Hospital of Sichuan University
32069401	27	Design, Synthesis, and Biological Evaluation of Imidazo[1,2-	East China Normal University
31033293	77	Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3K?-PI3K? Dual Inhibitors.	Hutchison Medipharma
30418766	35	Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.	Qingdao University
30530193	64	Targeting the immunity protein kinases for immuno-oncology.	China Pharmaceutical University
30015489	16	Atropisomerism by Design: Discovery of a Selective and Stable Phosphoinositide 3-Kinase (PI3K) ? Inhibitor.	Gilead Sciences
31855425	224	Optimization of Orally Bioavailable PI3K? Inhibitors and Identification of Vps34 as a Key Selectivity Target.	Glaxosmithkline
31335136	29	Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis.	TBA
28106991	136	Discovery of a Phosphoinositide 3-Kinase (PI3K) ?/? Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3K? Potency in a PI3K?-Selective Template by Targeting Nonconserved Asp856.	Gilead Sciences
30237123	12	Piperidinyl-embeded chalcones possessing anti PI3K? inhibitory properties exhibit anti-atopic properties in preclinical models.	Inserm 1052/Cnrs 5286/University of Lyon
29541370	41	Discovery of Pyridopyrimidinones as Potent and Orally Active Dual Inhibitors of PI3K/mTOR.	Wuxi Apptec (Shanghai) Co.
30077608	24	Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3K?.	China Pharmaceutical University
29631787	21	Discovery and biological evaluation of novel pyrazolopyridine derivatives as potent and orally available PI3K? inhibitors.	Astellas Pharma
29475582	8	Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3K? inhibition.	Shenyang Pharmaceutical University
30034607	60	Discovery of an Orally Bioavailable Dual PI3K/mTOR Inhibitor Based on Sulfonyl-Substituted Morpholinopyrimidines.	Shanghai Haiyan Pharmaceutical Technology
29017786	35	Identification of novel PI3K inhibitors through a scaffold hopping strategy.	Spanish National Cancer Research Centre (Cnio)
28958845	147	Synthesis and biological evaluation of sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474.	University of Auckland
30351000	119	Discovery of a Novel Inhaled PI3K? Inhibitor for the Treatment of Respiratory Diseases.	TBA
28494256	11	Designing multi-targeted agents: An emerging anticancer drug discovery paradigm.	Hunan University of Chinese Medicine
29852070	101	Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-? Inhibitors.	Pharmaron-Beijing
28404374	81	Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy.	Spanish National Cancer Research Centre (Cnio)
28520415	91	Design and Synthesis of Soluble and Cell-Permeable PI3K? Inhibitors for Long-Acting Inhaled Administration.	Astrazeneca
17685602	33	Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction.	Targegen
17172449	20	Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.	Targegen
18754654	19	The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .	Piramed Pharma